To develop a noninvasive algorithm for diagnosis of liver steatosis and to compare its diagnostic value with available predictive models.
L iver steatosis, characterized by abnormal fat accumulation in hepatic parenchyma, represents the most frequent liver disease worldwide 1 and it has been associated with presence of metabolic features. 2, 3 Liver biopsy has been used as the gold standard for diagnosis of liver steatosis. However, this invasive method has been challenged by limited feasibility and potential adverse events. 4 Noninvasive methods, as imaging techniques and serological markers, has been developed and validated in the last decade. 5 The advantage of serological tests relies on the combination of demographic and laboratory parameters to identify the presence of liver fat at low cost. Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), and Nonalcoholic Fatty Liver Disease-Liver Fat Score (NAFLD-LFS) are the most studied serological tests to detect liver steatosis. 6 The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), a multicenter cohort study, is a unique opportunity to evaluate risk factors for liver steatosis and to propose an algorithm to detect liver fat based on anthropometric measures and blood tests. 7 Previously, we assessed the accuracy of FLI and HSI in a subsample (n = 195) of participants from the ELSA-Brasil. 8 The aims of the present study were to develop a new algorithm for diagnosis of liver steatosis and to compare its diagnostic value with available serological tests.
MATERIALS AND METHODS

ELSA-Brasil Study
The ELSA-Brasil study enrolled active or retired public servants [n = 15,105; aged 35 to 74 years; 46% male; 30% with body mass index (BMI) > 30 Kg/m 2 ] from 6 Brazilian cities: Belo Horizonte, Porto Alegre, Rio de Janeiro, São Paulo, Salvador, and Vitória. 9 The primary aim of ELSA-Brasil study was to investigate the incidence and determinants of chronic noncommunicable diseases during a long-term follow-up. In the baseline visit (2008 to 2010) participants were submitted to clinical evaluation and anthropometric measures, blood tests and abdominal ultrasound (US). 10, 11 The study was approved by the Brazilian National Ethical Committee (CONEP) and Local Ethics Committees. All participants signed an informed consent upon enrollment in the ELSA-Brasil study.
Study Design
This cross-sectional study analyzed baseline data from the ELSA-Brasil. We excluded the participants without abdominal US (images not recorded or inadequate US images according to a senior US radiologist from a centralized analysis site), 8 those with abusive alcohol intake ( > 210 g/wk for men and > 140 g/wk for women) or missing data for metabolic features. Subjects included in the present analysis were randomly divided into training cohort (twothird of the subjects) and validation cohort (one-third of the subjects) to build and to validate the new predictive model for detection of steatosis, respectively.
Clinical Evaluation and Blood Tests
Clinical records included the measures of BMI, waist circumference (WC), blood pressure (the mean of 2 measurements) and alcohol consumption (quantified in g/wk and drinking patterns), and smoking (never, past, or current). 11 Blood tests were performed after an overnight fasting and analyzed in a central laboratory using an ADVIA 1200 and Centaur Siemens analyzer (Siemens, Illinois). 9,10 Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by enzymatic and γ-glutamyltransferase by kinetic colorimetric assay. The upper limit of normal of aminotransferases values were 43 IU/L and 35 IU/L for ALT and AST, respectively, in men and 36 IU/L and 31 IU/L in women. Plasma levels of total and high-density lipoproteincholesterol and triglycerides were determined by enzymatic methods. Low-density lipoprotein-cholesterol were calculated using the Friedewald equation or measured by enzymatic colorimetric assay if triglycerides > 400 mg/dL. Glucose and glycated hemoglobin (HbA1c) were measured using hexokinase method and high-pressure liquid chromatography, respectively. Fasting insulin was determined by immunoenzymatic assay (ELISA). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as HOMA-IR = [fasting glucose (mg/dL)×fasting insulin (μUI/mL)]/405 12 and insulin resistance was defined as HOMA-IR > 2.7 as previously validated. 13 Impaired glucose was defined as oral glucose tolerance test > 140 mg/dL and <200 mg/dL. Central obesity, dyslipidemia, 14 blood hypertension, 15 diabetes, 16 and metabolic syndrome were defined according to the International Diabetes Federation criteria. 17 
Abdominal US
Abdominal US were performed using a high-resolution B-mode scanner (SSA-790A, Aplio XG; Toshiba Medical System, Tokyo, Japan) and a convex array transducer (model PVT-375BT). Operators were previously trained in the University of São Paulo (ELSA-São Paulo site) before enrollment of the participants. Hepatic US images were recorded and analyzed by a centralized reading center at the ELSA-São Paulo site. The quality control of all abdominal US images was verified by a senior US radiologist, following a standardized protocol.
Liver steatosis was defined based on the evaluation of hepatic attenuation on B-mode images of abdominal US, loss of definition of the diaphragm and poor delineation of the intrahepatic architecture. 11 Absence of steatosis (grade 0) was defined as normal hepatic attenuation with complete diaphragm visualization. Presence of steatosis was classified as mild (grade 1: > 50% visualization of the diaphragm); moderate (grade 2: <50% visualization of the diaphragm); or severe (grade 3: poor or no visualization of the diaphragm) as previously validated. 8 Liver Steatosis Predictive Models Previously Reported in the Literature FLI includes BMI, WC, triglycerides and γ-glutamyltransferase; HSI uses transaminases, BMI and the presence of type-2 diabetes adjusted for gender and NAFLD-LFS includes fasting insulin, AST, ALT and presence of metabolic syndrome, and type-2 diabetes. These tests were calculated according to the following formulas:
Presence of liver steatosis was defined as FLI ≥ 60 18 , HSI ≥ 36 19 or NAFLD-LFS ≥ −0.640. 20
Development of a New Predictive Model for Liver Steatosis Diagnosis
Parameters used for calculation of Steato-ELSA were identified in a backward stepwise multivariate logistic regression model, which included variables significantly associated with liver steatosis by abdominal US (grade ≥ 1) in univariate analysis from the training cohort. All predictors besides gender were evaluated as continuous variables in the final model. Regression coefficients (β) of variables independently associated with steatosis in the final model, as well 
Statistical Analyses
Categorical variables were reported as absolute (n) and relative frequency (%) and continuous variables as median and interquartile range (IQR). χ 2 and Student t tests were used for comparisons of frequencies or means, respectively. A univariate logistic regression analysis was performed to estimate the odds ratios and confidence intervals (CIs) for the presence of steatosis. Backward stepwise multivariable logistic regression analysis was performed to build the Steato-ELSA. The severity of multicollinearity of variables entered into the final model was evaluated by the variance inflation factor (VIF) 21 and the final model goodness of fit was evaluated using the Hosmer-Lemeshow statistic. 22 Receiver-operator characteristic (ROC) curves analyses were performed and the optimal cutoff points were identified using the maximal Youden index. The diagnostic value of tests were assessed using sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and area under the ROC (AUROC) that were compared using the empirical nonparametric method according to Delong et al. 23 Statistical analyses were performed using STATA (StataCorp LP, College Station, TX).
RESULTS
A total of 15,105 subjects were included in the ELSA-Brasil study between 2008 and 2010. For the present analysis we excluded subjects without abdominal US (n = 2486) or when this examination was inadequate for steatosis detection (n = 2116). In addition, 646 subjects were excluded due to abusive alcohol intake or missing data on metabolic features. Therefore, 9857 subjects [58% female; median (IQR) age = 51 (45 to 58) years, BMI = 26.4 (23.9 to 29.6) Kg/m 2 , and ALT = 23 (18 to 32) IU/L; 38% with metabolic syndrome] were included ( Fig. 1 ). Subjects included in the training (n = 6571) and in the validation (n = 3286) cohort had similar age and proportion of women/men, metabolic features, blood test results, and prevalence of steatosis according to abdominal US ( Table 1) . Prevalence of at least mild steatosis (grade ≥ 1) was 38% (n = 2476/6571) and 37% (n = 1227/3286) in training and validation cohorts, respectively. In addition, moderate steatosis (grade ≥ 2) was present in 14% (n = 940/6571) and 13% (n = 442/3286) of participants in the training and validation cohorts, respectively.
Factors Independently Associated With Steatosis and Included in the Steato-ELSA Formula
In the training cohort, subjects with steatosis (grade ≥ 1) were older and more frequently male and had higher alcohol consumption (g/wk), BMI, WC, HOMA-IR, liver enzymes, and lipid parameters compared with those without steatosis (P < 0.001 for all). Table 2 ). Using this model, Steato-ELSA was calculated according to the following formula:
In the training cohort, the median (IQR) Steato-ELSA value was 0.260 (0.169 to 0.399) in individuals without steatosis; 0.415 (0.284 to 0.573) in subjects with grade 1 steatosis; 0.588 (0.430 to 0.738) with grade 2 steatosis, and 0.714 (0.524 to 0.824) with grade 3 steatosis. In the validation cohort, median (IQR) Steato-ELSA values were 0.260 (0.168 to 0.395), 0.410 (0.277 to 0.577), 0.602 (0.442 to 0.737), and 0.685 (0.600 to 0.841) for subjects without steatosis, and with grades 1, 2, and 3 steatosis, respectively (Fig. 2) . This predictive model was correlated [Spearman rho (P value)] with the presence of mild steatosis [rho = 0.44 (P < 0.001) for both cohorts] and moderate steatosis [0.38 (P < 0.001) for training and 0.40 (P < 0.001) for validation cohort].
Diagnostic Accuracy of Predictive Models for Liver Steatosis Diagnosis
In the training cohort, AUROCs (95% CI) of Steato-ELSA, FLI, HSI, and NAFLD-LFS for prediction of mild steatosis were 0.759 (0.747-0.771), 0.750 (0.738-0.762), 0.730 (0.717-0.742), and 0.711 (0.698-0.724) (P < 0.0001), respectively. In 2-by-2 comparisons, the AUROC of Steato-ELSA was significantly higher than FLI (P = 0.0013), HSI (P < 0.0001), and NAFLD-LFS (P < 0.0001). For prediction of moderate steatosis, the AUROCs (95% CI) were 0.820 (0.807-0.834) for Steato-ELSA, 0.808 (0.794-0.822) for FLI, 0.787 (0.761-0.792) for HSI and 0.776 (0.761-0.792) for NAFLD (P < 0.0001) ( Table 3 ). The AUROC of Steato-ELSA was significantly higher than FLI, HSI, and NAFLD-LFS (P < 0.0001 in 2-by-2 comparisons). The maximal Youden index was applied to determine the optimal cutoff for Steato-ELSA for presence of mild (Table 4 ).
In the validation cohort, the AUROCs (95% CI) for prediction of mild and moderate steatosis were: (i) 0.768 (0.751-0.784) and 0.829 (0.810-0.848) for Steato-ELSA; (ii) 0.762 (0.745-0.779) and 0.819 (0.799-0.838) for FLI; (iii) 0.743 (0.727-0.761) and 0.800 (0.779-0.822) for HSI; and (iv) 0.719 (0.701-0.737) and 0.769 (0.747-0.791) for NAFLD-LFS ( Table 3 ). The AUROCs of Steato-ELSA were significantly higher than FLI, his, and NAFLD-LFS for diagnosis of mild steatosis (P < 0.0001 for all comparisons) and moderate steatosis (P < 0.0001 for all comparisons). In addition, AUROCs (95% CI) for prediction of moderate steatosis were significantly better in white compared with black subjects Table 4 ). AUROCs of Steato-ELSA for detection of steatosis (grade ≥ 1) and moderate steatosis (grade ≥ 2) in training and validation cohorts are plotted in Figure 3 .
DISCUSSION
This study highlighted the diagnostic accuracy of serological tests and developed a new predictive model for diagnosisi of liver steatosis. Steato-ELSA can predict the presence of steatosis using clinical (BMI and WC) and laboratory data (glucose, insulinemia, tryglicerides, and transaminases). Persons with only hepatic steatosis are thought to have a benign long-term prognosis. However, 20% to 30% of those with simple steatosis develop nonalcoholic steatohepatitis (NASH), which may further progress to cirrhosis and its complications. 24 Identification of high-risk subjects for presence of hepatic steatosis is essential to prevent development of liver-related complications. 25 Steato-ELSA was developed and validated in a large sample size of subjects from Brazil, the largest country in Latin American, and used landmarks of insulin resistance in this formula, such as HOMA-IR and obesity. Therefore, this new predictive model can be used to identify this subset of high-risk individuals that should be further evaluated for presence of advanced fibrosis and referred for modification of lifestyle habits. In the present study, Steato-ELSA performed significantly better than FLI, HSI, and NAFLD-LFS in predicting mild and moderate steatosis in both training and validation cohort.
FLI and HSI were validated using abdominal US and NAFLD-LFS using magnetic resonance spectroscopy (MRS) as the reference. FLI was developed in a sample of individuals with suspected liver disease (n = 216) and matched controls (n = 280) in Italy. For diagnosis of steatosis, AUROC was 0.84 (95% CI, 0.81-0.87) and FLI ≥ 60 had a high specificity (87%). 18 HSI was validated in Korean subjects (5362 individuals with steatosis and 5362 age-matched and gendermatched controls) submitted to a medical check-up. HSI had an AUROC of 0.812 (95% CI, 0.801-0.824) and values > 36 had a specificity of 92% for detection of steatosis. 19 Finally, NAFLD-LFS was developed in a sample of 470 subjects (57% with metabolic syndrome) with chronically elevated transaminases in Finland. The AUROC of NAFLD-LFS was 0.86 (95% CI, 0.80-0.92) and values > −0.640 predicted steatosis with a sensitivity of 86% and specificity of 71%. 20 In the present study, Steato-ELSA performed significantly better than other models for diagnosis of mild and moderate steatosis in training and validation cohorts. This might be due to use of HOMA-IR, since insulin resistance is key to the pathogenesis of liver fat accumulation. Besides, potential collinearity for obesity assessment, BMI, and WC were entered in the formula. BMI has been limited by factors such as body size and body fat distribution 26 and WC has been observed to be a stronger predictor of obesity-related risk factors than BMI. 27 In addition, there was no severe collinearity (VIF values > 5) between both variables in the final multivariate model ( Table 2 ). The accuracy of FLI, HSI, and NAFLD-LFS were lower in Brazilian subjects compared with the studies that described these predictive models. [18] [19] [20] Differences in population characteristics or methods for determination of steatosis might explain those discrepancies. Xia et al 28 reported the impact of ethnicity on the accuracy of FLI, HSI, and NAFLD-LS for predicting liver steatosis using MRS as the gold standard: AUROCs were 0.77 in Chinese subjects (n = 3548) and ranged from 0.72 to 0.81 in Finnish people (n = 572). Using US as the reference, the AUROCs (95% CI) of FLI for detection of steatosis were 0.827 (0.822-0.831) in Taiwanese individuals (n = 29,797), 29 0.813 (0.797-0.830) in Netherlands (n = 2652), 30 and 0.78 (0.74-0.81) in the United States (n = 5869). 31 In a sensitivity analysis according to ethnicity and gender, Steato-ELSA seems to perform better in White than African-Black and female than male subjects. In addition, Steato-ELSA performed significantly better than HSI and NAFLD-LFS despite differences in gender or ethnicity (Supplementary Table1, Supplemental Digital Content 1, http://links.lww.com/JCG/A383). Ruhl and Everhart 31 proposed a FLI score adapted for multiethnic North-American population adding fasting insulin, glucose and ethnicity to this calculation, which performed slightly better than FLI 32 Liver steatosis can be detected based on hepatic parenchyma echogenicity or attenuation of the US wave leading to loss of definition of diaphragm and blurring vascular margins. 5 The accuracy of US for detection of steatosis ( > 10% hepatocytes) was validated [0.93 (95% CI, Training cohort: *higher than FLI (P = 0.0013); HSI (P < 0.0001), and NAFLD-LFS (P < 0.0001). †Higher than HSI (P < 0.0001) and NAFLD-LFS (P < 0.0001). ‡Higher than NAFLD-LFS (P = 0.0002). §Higher than FLI (P < 0.0001); HSI (P < 0.0001), and NAFLD-LFS (P < 0.0001). ‖Higher than HSI (P = 0.0001) and NAFLD-LFS (P < 0.0001). ¶Higher than NAFLD-LFS (P = 0.0066).
Validation cohort: #higher than FLI (P < 0.0001); HSI (P < 0.0001), and NAFLD-LFS (P < 0.0001). **Higher than HSI (P = 0.0028) and NAFLD-LFS (P < 0.0001). † †Higher than NAFLD-LFS (P = 0.0017). ‡ ‡Higher than FLI (P < 0.0001), HSI (P < 0.0001), and NAFLD-LFS (P < 0.0001). § §Higher than HSI (P = 0.0132) and NAFLD-LFS (P = 0.0003). AUROC indicates area under the receiver-operator curve; CI, confidence interval; FLI, Fatty Liver Index; HSI, Hepatic Steatosis Index; NAFLD-LFS, Nonalcoholic Fatty Liver Disease-Liver Fat Score. 0.91-0.95)] in a meta-analysis (n = 2815 participants) which included 34 studies that used liver biopsy as the reference. 33 We previously validated the analysis of liver attenuation by US for steatosis detection using 64 channel high-resolution computed tomography as the gold standard [0.84 (95% CI, 0.77-0.90)]. 8 However, this method has a considerable interobserver variability and sensitivity might be reduced in presence of <30% of fat infiltration. 34 In a study (n = 324) which liver biopsy was the gold standard, FLI, HSI, and NAFLD-LFS yielded AUROCs of 0.83 (0.72-0.91), 0.81 (0.71-0.88), and 0.80 (0.69-0.88), respectively, for steatosis detection ( > 5% hepatocytes). However, these noninvasive tests were less accurate for detection of moderate/severe steatosis ( > 33%). 35 Differences in prevalence of steatosis grades might impact in diagnostic test's performance, known as spectrum bias. 36 FLI and HSI were developed in case-control studies, whereas NAFLD-LFS and Steato-ELSA in cross-sectional studies with prospective inclusion of subjects. Prevalence of steatosis was extremely variable in the studies that validated the diagnostic value of noninvasive tests for detection of steatosis using abdominal US as the reference. In the present study the prevalence of mild (grade ≥ 1) and moderate (grade ≥ 2) steatosis were 38% (n = 3703) and 14% (n = 1382), respectively. We are aware that fatty liver is strongly associated with insulin resistance, 37 but the need of insulinemia might be a concern for Steato-ELSA calculation. In absence of fasting insulin, Steato-ELSA without HOMA-IR might be calculated (Supplementary Tables 2  and 3 , Supplemental Digital Content 1, http://links.lww. com/JCG/A383).
A major limitation of this study was the absence of liver biopsy to assess the diagnostic performance of predictive models for detection of steatosis. However, it might be unethical to perform liver biopsy in subjects without suspicion of liver disease as ELSA-Brasil population. MRS could be used to replace liver biopsy as the gold standard. However, this method is costly and not widely available despite its excellent sensitivity and high reproducibility. 38 We acknowledge that US has lower sensitivity in presence of mild fat infiltration, but abnormalities in hepatic echogenicity or attenuation of US waves were validated to detect steatosis. 33 Other potential criticisms should be the limited sample size of subjects with severe steatosis (n = 206/9587), the lack of evaluation of the impact of liver fibrosis on noninvasive tests' performance and the absence of screening for chronic liver disease in the study population. The AUROCs (95% CI) of Steato-ELSA for severe steatosis (grade = 3) were 0.848 (0.820-0.875) and 0.869 (0.831-0.907) in the training and validation cohort, respectively. Subjects included in the analysis did not have known chronic liver diseases. In addition, the very low prevalence (< 1%) of necroinflammatory activity (ALT levels > 3× upper limit of normal) and advanced fibrosis (METAVIR F3F4) using a noninvasive test (FIB-4 ≥ 3.25) minimized the potential bias of lacking screening of chronic viral hepatitis in the ELSA-Brasil study. We acknowledge a potential selection bias by exclusion of 5248 subjects who were significantly older, more frequently male and had higher BMI, WC liver enzymes and lipid parameters compared with those included in the study (Supplementary Table 4 , Supplemental Digital Content 1, http://links.lww.com/JCG/A383). The strengths of our study include large size of study population and the use of a centralized laboratory for blood tests and a centralized and blinded reading center for analysis of recorded hepatic images to determine steatosis degrees. Despite the fact that this is not a population-based study, we included 9587 subjects from 6 Brazilian centers.
In conclusion, available predictive models using serological parameters and the new proposed Steato-ELSA are accurate and inexpensive tools for identifying individuals at high risk of liver steatosis. These noninvasive tests can be used to select individuals for screening of liver fibrosis related to NAFLD or to be referred for modification of lifestyle habits. Even though Steato-ELSA seems to be an accurate predictive model for detection of liver steatosis, this noninvasive test must be further validated in studies including different populations with different chronic liver diseases.
